<DOC>
	<DOCNO>NCT00892775</DOCNO>
	<brief_summary>This study undertaken generate clinical data GSK Biologicals ' combined measles-mumps-rubella-varicella vaccine manufacture measles rubella obtain newly establish work seed viruses one passage current work seed virus . The measles-mumps-rubella-varicella vaccine manufacture current work seed virus serve comparator . A seed lot system system accord successive batch vaccine derive master seed virus . For routine production , work seed lot prepare master seed virus .</brief_summary>
	<brief_title>Immunogenicity &amp; Safety Study GSK Biologicals ' 208136 Vaccine Formulated With New Measles Rubella Working Seeds</brief_title>
	<detailed_description />
	<mesh_term>Measles</mesh_term>
	<mesh_term>Rubella</mesh_term>
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parents/guardians comply requirement protocol ( e.g . completion diary card , return followup visit ) enrol study . A male female , include , 11 21 month age ( e.g . age 11months day age 22 month ) time first vaccination . Written inform consent obtain parent guardian subject advise risk benefit study language clearly understand , performance study procedure . Free obvious healthy problem establish medical history clinical examination enter study . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . Administration immunoglobulins and/or blood product six month enter study plan administration study period . Planned administration/ administration vaccine foreseen study protocol within 30 day prior 42 day study vaccine dose exception oral polio vaccine ( OPV ) give time routine inactivate vaccine pneumococcal , meningococcal Haemophilus influenzae type b conjugate vaccine , inactivate influenza diphtheria/tetanus contain vaccine administer eight day study vaccine dose . Previous vaccination measles , mumps , rubella and/or varicella . History measles , mumps , rubella and/or varicella/zoster disease . Known exposure measles , mumps , rubella and/or varicella within 30 day prior study start . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . A family history congenital hereditary immunodeficiency . History allergic disease reaction likely exacerbate component vaccine ( ) , include systemic hypersensitivity neomycin . Major congenital defect serious chronic illness . History neurologic disorder seizure . Acute disease time enrolment . Rectal temperature ≥38°C axillary temperature &gt; =37.5°C time vaccination . Residence household high risk person e.g . : Newborn infant ( 04 week age ) Pregnant woman negative history chickenpox Persons known immunodeficiency</criteria>
	<gender>All</gender>
	<minimum_age>11 Months</minimum_age>
	<maximum_age>21 Months</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Working seed virus</keyword>
	<keyword>Rubella</keyword>
	<keyword>Mumps</keyword>
	<keyword>Varicella</keyword>
	<keyword>Combined measles-mumps-rubella-varicella vaccine</keyword>
	<keyword>Pediatric immunization</keyword>
	<keyword>Measles</keyword>
</DOC>